Sichenzia Ross Friedman Ference LLP Advises Sorrento Therapeutics, Inc. on $25.0 million Public Offering of Common Stock
NEW YORK, May 20, 2014 (GLOBE NEWSWIRE) — New York- based securities law firm, Sichenzia Ross Friedman Ference LLP announced that it has represented Sorrento Therapeutics, Inc. (NASDAQ: SRNE), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, in a $25.0 million public offering. The offering consists of 4,765,000 shares of common stock priced at $5.25 per share. The Sichenzia Ross Friedman Ference LLP team was led by partners Jeff Fessler and Marcelle Balcombe.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Sichenzia Ross Ference LLP Represents Document Security Systems, Inc. in $5.6 Million Underwritten Public Offering of Common Stock - June 11, 2019
- New Jersey Bureau of Securities Proposes New Rule to Create State-Level Fiduciary Duties For Broker-Dealers, Associated Persons, Investment Advisers and Investment Adviser Representatives - June 11, 2019
- Sichenzia Ross Ference LLP Represents Medicine Man Technologies, Inc. in Private Placement Offering of up to $14 Million - June 11, 2019